Pharmacyclics down 6%, still no Imbruvica CLL update
This article was originally published in Scrip
Executive Summary
Pharmacyclics saw its stock sink on the 9 December after extended Phase II trial data for oral Bruton's tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) was released at the 55th American Society for Hematology meeting in New Orleans. Although, the data continue to paint a positive picture, investors seem to be getting impatient for an update on the firms US CLL approval filing.